Nachrichten zur Hims & Hers Health Inc. Aktie

Hims & Hers Short Interest Hits 23% as Q3 Earnings Test Looms

Hims & Hers Health reports third-quarter results Monday with short interest at 23% and the stock down about 65% from…

Hims & Hers Health short interest rises to 23% ahead of Q3 results

Short interest in Hims & Hers Health rose to 23%, making it one of the most shorted mid-cap stocks. Stock…

Hims & Hers Short Interest Climbs to 23% Ahead of Earnings: Can the Stock Break Out?

Hims & Hers Health stock has lost momentum this year. After peaking at $72.78 in 2025, it has slumped about…

Eli Lilly Partners With Hims & Hers to Expand GLP-1 Access

Eli Lilly partners with Hims & Hers to expand access to obesity drugs, with CEO Andrew Dudum highlighting the benefits…

Is Hims & Hers Health (HIMS) A Bargain After Its Lilly Deal?

Eli Lilly’s new agreement with Hims & Hers Health (HIMS) puts Lilly’s obesity drugs Zepbound and Foundayo directly inside the…

Hims & Hers Health (HIMS) Could Be 85% Undervalued Following The Eli Lilly Deal

Hims & Hers Health (HIMS) just signed a new agreement with Eli Lilly that allows its users to access branded…

Hims Partnership Could Be A Big Deal For Eli Lilly (LLY)

Eli Lilly and Hims & Hers Health announced a partnership in early November 2026 that lets eligible patients obtain Zepbound…

Hims & Hers Stock After Lilly Weight Loss Drug Deal Has The Bull Case Changed?

Eli Lilly and Company announced an agreement with Hims & Hers Health to offer FDA-approved obesity drugs Zepbound and Foundayo…

Hims & Hers Health (HIMS) Adds FDA Approved Obesity Drugs To Its Platform

Hims & Hers Health (NYSE:HIMS) announced a new partnership with Eli Lilly to offer Zepbound and Foundayo on its platform.…

Hims & Hers and Intuitive Surgical Diverge on Growth Paths, Investors Must Weigh Risk Against Valuation

Investors seeking long-term growth often must weigh the disruptive potential of telehealth against the established dominance of medical robotics. Choosing…

Hims & Hers Health vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy for 2027?

Both are disruptors, but one of these growth stocks stands out over the other.…

Hims & Hers Health Inc (HIMS) Stock Up 8.1% and Still Undervalued -- GF Score: 77/100

On November 06, 2026, Hims & Hers Health Inc (HIMS) shares rose 8.1%, bringing the current price to $26.00. This…

Hims Stock In Focus As Benefits Program Expands Before Earnings

Hims & Hers Health recently expanded its Hims & Hers Benefits program, adding Grüns, Medjet, Tonal, and Viome to offer…

Hims & Hers inks deal with Eli Lilly to offer branded weight loss drugs

Hims & Hers struck a deal with Eli Lilly to offer the drugmaker’s branded obesity treatments through its online health…

Healthcare Stocks Were Flat, But Biotech Found A Pulse

Moderna raised its full-year outlook as Natera slid on a wider-than-expected Q3 loss and Hims & Hers gained on a…

Eli Lilly Integrates Zepbound and Foundayo Into Hims & Hers, Completing Cash-Pay GLP-1 Platform

Eli Lilly’s formal partnership with Hims & Hers puts Zepbound ($299/mo) and Foundayo ($149/mo) inside the telehealth platform as of…

Eli Lilly Picks Hims & Hers to Sell Its Obesity Drugs, Days Before Hims Reports

Key TakeawaysEli Lilly will let Hims & Hers sell its Zepbound and Foundayo obesity drugs directly on its platform, and…

Polymarket Odds: Will RKLB, HIMS, TTD Beat Earnings on Monday?

On Monday, November 9, Rocket Lab ($RKLB), Hims & Hers ($HIMS), and Trade Desk ($TTD) will report their earnings. All…

Eli Lilly (LLY) Widens Access To Its Obesity Drugs Through Telehealth

Eli Lilly (NYSE:LLY) is partnering with Hims & Hers Health and LifeMD to offer FDA-approved obesity drugs through telehealth platforms.The…

Hims & Hers Gained as the Market Dipped. Here’s What the November 9 Report Must Prove

Revenue’s the easy part this time…

Why is Hims & Hers Health stock rallying today?

Why is Hims & Hers Health stock rallying today?…

Eli Lilly Teams Up With Hims Platform for Direct Delivery of Weight-Loss Drugs as Cash-Pay Channel Battle Heats Up

Eli Lilly and telehealth platform Hims & Hers announced a partnership on Friday under which Hims users who complete an…

Hims & Hers stock climbs on direct partnership with Eli Lilly for obesity drugs

Hims & Hers stock climbs on direct partnership with Eli Lilly for obesity drugs…

Hims & Hers Partners with Eli Lilly for Direct Weight Loss Drug Delivery - Eli Lilly (NYSE:LLY), Hims & Hers…

Eli Lilly partners with Hims & Hers to offer Zepbound and Foundayo directly to telehealth patients with self-pay options starting…

Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.

As part of the agreement, Hims said it won’t compound GLP-1 medications like Zepbound in the future.…

Hims & Hers rises 5% as Eli Lilly deal brings $149 obesity pill access

Telehealth provider Hims & Hers Health (NYSE:HIMS) shares rose 5% to $25.32 during the Nov. 6 trading session. In a…

Hims & Hers bietet Lillys Abnehmmittel an: Die Telemedizin-Plattform erhält direkten Zugang zu Zepbound und Foundayo zu Selbstzahlerpreisen!

Eli Lilly und Hims & Hers vereinbaren, dass Patienten der Telemedizin-Plattform Lillys zugelassene Abnehmmittel direkt über Hims & Hers beziehen…

Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Rybrevant Faspro

Hims & Hers partners with Eli Lilly to sell Zepbound and Foundayo directly on its platform, Novo Nordisk terminates its…

Lilly strikes obesity drug access deal with Hims & Hers telehealth

Lilly partners with Hims & Hers to offer Zepbound and Foundayo directly through its platform, with monthly self-pay prices starting…

HIMS Q3 Earnings: Can Weight Loss Momentum Drive Performance?

Hims & Hers Health gears up for Q3 earnings, with weight loss demand, international expansion and subscriber growth fueling revenues…

HIMS Q3 Earnings: Can Weight Loss Momentum Drive Performance?

Hims & Hers Health HIMS is scheduled to report third-quarter 2026 results on Nov. 9, after market close. The company is…

Lilly to sell Zepbound and Foundayo on Hims & Hers platform

Eli Lilly will sell obesity drugs Zepbound and Foundayo directly through Hims & Hers in the United States under an…

HIMS climbs over 4% after unveiling four new Benefits platform partnerships

Hims & Hers Health surges 4.03% today, closing at $25.03 as new Benefits partners lift momentum despite ongoing selling pressure.…

Hims & Hers Rises 4% as Eli Lilly Deal Brings Zepbound to Its Platform: “A Clear Positive”

More customers, sure. The question is what each one’s worth.…

Hims Surges On Surprising And Inevitable Deal With Eli Lilly

Hims & Hers Health inked a deal with Eli Lilly on Friday to sell the companys obesity drugs.…

Eli Lilly is partnering with Hims & Hers to sell its weight loss drugs

The agreement covers Zepbound and Foundayo for patients who pay out of pocket through the telehealth platform…

Why Hims & Hers Health Stock Was in Dire Need of This Eli Lilly Agreement

Hims & Hers stock rises after the company announces an agreement with Eli Lilly to offer the pharma giant’s GLP-1s…

Lilly to sell obesity drugs directly on Hims & Hers site

Nov 6 (Reuters) - Eli Lilly said on Friday it struck a deal to allow Hims & Hers Health to…

Eli Lilly teams up with Hims & Hers on obesity drugs

Hims & Hers already has a similar partnership with Denmark’s Novo Nordisk.…

Eli Lilly Partners With Hims & Hers to Expand Access to Obesity Treatments Through Telehealth

Eli Lilly and Company (NYSE:LLY) and Hims & Hers Health, Inc. (NYSE:HIMS) have announced an agreement to make two of…

Lilly to sell obesity drugs directly on Hims & Hers site

Lilly will sell obesity drugs Zepbound and Foundayo directly on the Hims & Hers telehealth platform…

Hims & Hers gains on partnership with Eli Lilly

Hims & Hers Health (HIMS) stock rises as the company inks a partnership to sell Eli Lillys (LLY) weight-loss drugs,…

Lilly and Hims & Hers Formalize Self-Pay Obesity Drug Access

Eli Lilly and Hims & Hers announced an agreement on November 6, 2026 to expand access to Zepbound and Foundayo…

Lilly and Hims & Hers expand access to FDA-approved Lilly medicines

Agreement gives patients a path to FDA-approved treatments at self-pay price through the Hims Hers platform Eli Lilly and…

Lilly partners with Hims & Hers on obesity drug sales

Eli Lilly has signed an agreement with Hims & Hers that will see its weight-loss therapies sold directly on the…

Lilly and Hims & Hers strike deal for obesity drugs on telehealth platform

Eli Lilly and Company (NYSE: LLY) and Hims & Hers Health, Inc. (NYSE: HIMS) announced an agreement to make two…

Lilly to sell obesity drugs directly on Hims & Hers site | Business Information & News | FE

View on Westlaw or start a FREE TRIAL today, FE, Business Information & News…

Lilly to sell obesity drugs directly on Hims & Hers site

By Michael ErmanEli Lilly NYSE:LLY said on Friday it struck a deal to allow telehealth company Hims & Hers Health…

Lilly to sell obesity drugs directly on Hims & Hers site

Nov 6 (Reuters) - Eli Lilly said on Friday it struck a deal to allow telehealth company Hims & Hers…

Lilly partners with Hims & Hers to offer weight-loss drugs

Lilly partners with Hims & Hers to offer weight-loss drugs…